HDAC2 and chronic myelogenous leukemia, BCR-ABL1 positive: Typically, the CAY10683 combined with IM treatment has been suggested to exert a synergistic effect on handling the IM resistance problem in CML, which is majorly achieved through inhibiting HDAC2.